Try not to Miss these Medical VACC braindumps with Free PDF

killexams.com gives the Latest and 2022 refreshed killexams VACC Real Exam Questions with Actual VACC Test Questions for new subjects of Medical VACC Exam. Practice our Real VACC Questions Improve your insight and finish your test with High Marks. We ensure your accomplishment in the Test Center, covering every last one of the subjects of the test and improving your Knowledge of the VACC test. Pass with a 100 percent guarantee with our right inquiries.

Exam Code: VACC Practice exam 2022 by Killexams.com team
VACC Vascular Access
Medical Vascular candidate
Killexams : Medical Vascular candidate - BingNews https://killexams.com/pass4sure/exam-detail/VACC Search results Killexams : Medical Vascular candidate - BingNews https://killexams.com/pass4sure/exam-detail/VACC https://killexams.com/exam_list/Medical Killexams : Could Artificial Blood Actually Help with the Blood Shortage Crisis?

Thanks to the COVID-19 pandemic, blood shortages have become a full-blown crisis, according to data from the Red Cross. Around 40,000 pints of blood are transfused daily across the nation, showing just how vital the need for blood currently is.

Many scientists and medical companies are looking for ways to overcome this crisis and ensure there is enough blood for people who need it. One novel, but possible solution that is being studied involves the creation of synthetic, artificial blood. While this blood may be complex to create, if achieved it could potentially save an untold number of lives annually, and help to curb the current nationwide shortage. 

Background: What is Artificial Blood? 

Artificial blood is a blood-like substitute for actual blood and is solely used to transport oxygen through the body. Because of this, there needs to be the right amounts of hemoglobin in the artificial blood. According to the chief of the Laboratory of Biochemistry and Vascular Biology at the FDA’s Center for Biologics Evaluation and Research, Abdu Alayash, “Hemoglobin-based oxygen carriers (HBOCs) — also known as ‘blood substitutes’ — are manufactured using hemoglobin that has been removed from red cells. But because the hemoglobin in these carriers is no longer enclosed, it can undergo chemical changes that make it extremely reactive and toxic while circulating in the blood, causing damage to tissues.” With even just the tiniest change in environment, artificial blood can change into something no longer healthy for a patient. 

Analysis: How to Create Artificial Blood

The process of creating blood substitutes goes back centuries, beginning in the 1600s. At that time, individuals tried using substances like milk for transfusions, but with little success. Current methods to produce artificial blood include isolation of certain molecules, like hemoglobin, or recombination of different ingredients. These processes have yet to be proven successful, though various clinical trials are still ongoing.

Besides striking the right balance between different organic molecules, artificial blood needs to have a long shelf life in order to be stored for later use. Many companies are working on overcoming these challenges, some of them employing odd resources. For example, researchers at Villanova University are looking at using hemoglobin from earthworms. As Dr. Jacob Elmer, the lead researcher explained, “Earthworm hemoglobin has many favorable adaptations that make it a great blood substitute candidate, and preliminary studies have shown that they can safely deliver oxygen in mice and hamsters without the adverse effects of cow and human hemoglobin.” There is currently no commercial artificial blood product for hospitals or doctors to buy, but if there is one soon, experts predict it will generate at least $7.6 billion in just the U.S. alone. 

Outlook: A Shift in Regulations

Another reason why artificial blood hasn’t been commercialized yet is the strict regulations put in place. “The FDA has been the biggest impediment to the advancement of developing artificial oxygen carriers, despite multiple candidates,” explained professor emeritus at UCLA Anesthesiology, Jonathan Jahr.

“They must get beyond demanding a product with no side effects, as all drugs have side effects, including blood!” However, the growing blood shortage may change the regulation standards currently in place by the FDA, which may be driven to relax the rules in order to facilitate blood–and possibly synthetic substitutes–for those who need it. 

Kenna Hughes-Castleberry is a staff writer at the Debrief and the Science Communicator at JILA (a partnership between the University of Colorado Boulder and NIST). She focuses on deep tech, the metaverse, and quantum technology. You can find more of her work at her website: https://kennacastleberry.com/

Fri, 15 Jul 2022 01:26:00 -0500 en-US text/html https://thedebrief.org/could-artificial-blood-actually-help-with-the-blood-shortage-crisis/
Killexams : SafeHeal Appoints Medical Device Industry Veteran Chris Richardson as Chief Executive Officer

PARIS, FRANCE and TAMPA, FL / ACCESSWIRE / July 11, 2022 / SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately.

Sofinnova Partners, Monday, July 11, 2022, Press release picture

Richardson has over 30 years of experience in the medical device industry, and an extensive record of successfully taking medtech companies from startup to commercialization to acquisition. Most recently, he was President and CEO of Keystone Heart, a structural heart medical device company, and creator of the first Cerebral Embolic Protection device designed to provide complete coverage to all brain regions for patients undergoing cardiac procedures. Keystone Heart was acquired in 2018 by Venus Medtech, the leader in transcatheter structural heart valvular therapies in China.

Before that, Richardson was International President and Chief Commercial Officer of Direct Flow Medical, a transcatheter aortic valve company, and General Manager of Evalve (MitraClip), which was acquired by Abbott Vascular. He has served as Chairman of the Board of Directors at Neurolief, creator of a digital therapeutics platform based on a clinically-validated neuromodulation technology to treat chronic neurological and neuropsychiatric disorders such as migraine and depression.

'We're fortunate to have Chris come on board at this stage in SafeHeal's development,' said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, a cornerstone investor and a member of the company's Board of Directors. 'Chris has the experience and operational track record the company needs right now to execute on its ambitious plan to transform the standard of care for colorectal cancer patients.'

SafeHeal was founded in 2015 by the MD Start team, which leads Sofinnova Partners' in-house medtech accelerator. The company develops the Colovac device, designed to eliminate the need for diverting ostomies post Colorectal cancer resection. SafeHeal announced in April 2022 the first patient enrollment in its US pivotal study of Colovac, (SAFE 2) with as many as 20 U.S. and European sites enrolling patients in the study. In January, Sofinnova Partners, a historic shareholder in SafeHeal, co-led a €40 million financing round of the company, with Genesis MedTech.

'I'm delighted to be joining this talented team,' Richardson said. 'It's an exciting time for SafeHeal, building upon our European clinical success and preparing for EU commercial launch. Colovac has the potential to Improve the quality of life for millions of patients around the world and reshape colorectal surgery.'

Jay Watkins, Chairman of SafeHeal's Board of Directors, said Richardson was 'the perfect candidate for the CEO role. He has what it takes to bring SafeHeal to the next level - strategy-development skills, integrity, experience building teams, and much more.'

Richardson succeeds the previous CEO, Karl Blohm, who remains at the company as Vice President International.

About SafeHeal

SafeHeal is an early-stage medical device company in Paris with US operations in Tampa, FL. The company develops Colovac, a device designed to obviate the need for a digestive ostomy in patients undergoing colorectal surgery. The device is a flexible bypass sheath, intended to reduce any contact of fecal content at the anastomotic level, following colorectal surgery. Colovac is elegantly simple, minimally invasive, and fully reversible. The device remains in place for 10 days during anastomosis healing, after which it is removed during an endoscopic procedure, without the need for a second surgical intervention. This enables patients to resume their normal life without having to bear an artificial anus or stoma for several months. SafeHeal was founded by MD Start II. For more information about SafeHeal, visit: www.safeheal.com.

Contact:

Chris Richardson
CEO of SafeHeal
813-309-8577
crichardson@safeheal.com

SOURCE: SafeHeal

View source version on accesswire.com:
https://www.accesswire.com/708064/SafeHeal-Appoints-Medical-Device-Industry-Veteran-Chris-Richardson-as-Chief-Executive-Officer

Mon, 11 Jul 2022 01:25:00 -0500 en text/html https://www.bignewsnetwork.com/news/272616373/safeheal-appoints-medical-device-industry-veteran-chris-richardson-as-chief-executive-officer
Killexams : Flat Medical Enters the Vascular Access Medtech Domain with its Newly Acquired MDR Certification and New Medical Advisor

TAIPEI, July 12, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, announced that it has received Medical Device Regulation (MDR) certification from its Notified Body, the British Standards Institution (BSI), for its brand-new innovation, EpiFaith® CV, to deliver safe central line placements in European markets.

"This is a super exciting achievement for our team with significantly meaningful value," said Shao-Wei Tseng, the Chief Regulatory Officer of Flat Medical. "As the first Taiwanese Medtech company awarded MDR certification from the BSI, we feel honored to be certified to supply our innovative solution to Improve the safety and quality of central venous catheterization procedures."

Central venous catheterization (CVC) is a common procedure in anesthesia, emergency medicine, and intensive care practices. Despite being widely performed by physicians in different specialties, central line placement can sometimes become cumbersome and risky when patients are critically ill or in an emergency setting. EpiFaith® CV is an innovative auto-aspiring syringe that helps providers identify and access vessels easily and safely.

As part of its portfolio growth strategy, Flat Medical is announcing the appointment of Dr. Gregory Schears—a Professor at the Mayo Clinic and a world-renowned expert in intensive care and vascular access—to its scientific advisory board. "The EpiFaith® is an innovation that has the potential to help make the central line access a much safer procedure with the user-friendly design," said Dr. Gregory Schears. "I am happy that I can be of help on the development of the product and its clinical strategies."

Flat Medical is now organizing a product launch with its local partners in the U.S. and Europe. The EpiFaith® CV has been formally introduced at the European Society of Anaesthesiology and Intensive Care (ESAIC) annual meeting this June in Milan and will be shown at the upcoming Association for Vascular Access (AVA) annual meeting in Minneapolis, and the European Society of Intensive Care Medicine (ESICM) annual congress in Paris.

About Flat Medical Co., Ltd.

Flat Medical is a MedTech company that focuses on safety solutions for clinical procedures. Supported by key opinion leaders and venture capitalists in the United States, Europe, and Asia, the company is commercializing and developing various applications for its innovative EpiFaith® tech.

CONTACT: Karl Tsao, karltsao@flatmedical.com

Cision View original content:https://www.prnewswire.com/news-releases/flat-medical-enters-the-vascular-access-medtech-domain-with-its-newly-acquired-mdr-certification-and-new-medical-advisor-301584798.html

SOURCE Flat Medical Co., Ltd.

Tue, 12 Jul 2022 01:59:00 -0500 en-US text/html https://www.abc27.com/business/press-releases/cision/20220712HK14425/flat-medical-enters-the-vascular-access-medtech-domain-with-its-newly-acquired-mdr-certification-and-new-medical-advisor/
Killexams : Most Americans have poor cardiometabolic health – here's what they can do to change that

The medical community has been concerned about Americans' cardiometabolic health for years, but the crisis appears to be getting worse.

Less than 7% of U.S. adults are in good cardiometabolic health, a new study suggests. But what exactly does cardiometabolic health refer to? And how can people Improve their own health? 

What is cardiometabolic health? 

Cardiometabolic health is a spectrum of conditions and risk factors that often occur together and are a significant cause of cardiovascular disease. They include metabolic syndrome, type 2 diabetes, obesity, high cholesterol and blood pressure.

Each of these factors can increase the risk of heart disease. Diabetes, in particular, more than doubles the risk of cardiovascular disease. But when combined, they increase the risk of experiencing an early heart attack, stroke or peripheral vascular disease, according to the Cleveland Clinic

A lack of physical activity is also a significant contributor to poor cardiometabolic health, the researchers found. Americans are not only not exercising as much, but they also are living more sedentary lives.

"While we know that cardiometabolic health among Americans is a significant problem, we were surprised by the magnitude of the crisis," researcher Meghan O’Hearn, a doctoral candidate at the Friedman School of Nutrition Science and Policy at Tufts University, told U.S. News & World Report. "The lack of good health and well-being across the board is truly devastating and has only been getting worse."

A worsening situation 

The number of U.S. adults with healthy weights and blood sugar continues to decline at a fast pace, researchers found. The study included 55,000 adults who answered a national health and nutrition survey between 1999 and 2018. 

In 1999, 1 in 3 adults were at a normal weight, but that had dipped to 1 in 4 by 2018. And the number of adults living without prediabetes or diabetes dropped from 6 in 10 to less than 4 in 10. (People with prediabetes have blood sugar levels that are elevated but not high enough for a diabetes diagnosis.)

The researchers also found that cardiometabolic health varied by sex, race, ethnicity and education. Adults with less education, and those who were Hispanic or Black, were less likely to have good cardiometabolic health.

This suggests that social determinants of health, such as food and nutrition security, economic stability and structural racism, may be contributing factors, the researchers noted. They called for better access to healthy foods and more education on how to achieve a healthier diet.

In an editorial accompanying the study, cardiologists Drs. Thomas E. Kottke, Ajay K. Gupta and Randal J. Thomas wrote that the worsening cardiometabolic health of Americans should not be a surprise considering the predominance of unhealthy lifestyle behaviors. They include diets high in saturated fat, sugar, salt and calories; little to no physical activity; high alcohol consumptions; poor sleep habits and too much screen time. 

To encourage healthy behavioral changes on the individual level, there needs to be more support on the community level, they wrote. This includes alliances with hospitals and schools to promote healthier eating and to ensure that students have enough opportunities for physical activity throughout the day. Alliances with city planning, transportation and parks and recreation also can increase opportunities for physical activity.

How to Improve cardiometabolic health

There are steps people can take to Improve their cardiometabolic health

To start, eat a diet mostly comprised of whole, unprocessed vegetables, some lean meats and fish, whole grains, nuts and seeds, legumes, dairy, and extra virgin oil, spices and herbs for seasoning. Fish, green leafy vegetables, onions, tomatoes, blueberries, yogurt and oats are particularly good for cardiometabolic health. Also, keep alcoholic consumption to an occasional treat.

Finding more ways to move throughout the day is also important. Researchers emphasize that it is not enough to go to the gym a couple times a week. People need to be moving throughout the day, every day. 

Some people have found that using standing desks at work or holding "walking" meetings can help decrease sedentary time. So can limiting screen time at home.

Better stress management and getting a good night's sleep every night also can optimize cardiometabolic profile, scientists say.

Mon, 04 Jul 2022 12:00:00 -0500 text/html https://www.phillyvoice.com/cardiometabolic-health-definition-heart-disease-obesity-diabetes/
Killexams : Inventiva begins screening in NASH and type-2 diabetes Phase IIa study

Inventiva has announced screening of first participant in LEGEND Phase IIa combination trial of the company’s lead product candidate, lanifibranor, along with empagliflozin.

The orally available small molecule, lanifibranor activates all three-peroxisome proliferator-activated receptor (PPAR) isoforms in order to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body.

The placebo-controlled, multi-centre, randomised, Phase IIa proof-of-concept study has been designed to evaluate the efficacy and safety of lanifibranor along with empagliflozin to treat non-cirrhotic non-alcoholic steatohepatitis (NASH) and type-2 diabetes (T2D) in adult patients.

The company stated that the trial is an open label for the combination of lanifibranor and the SGLT2 inhibitor empagliflozin arm and double-blind for the placebo and lanifibranor arms.

A total of 63 participants with non-cirrhotic NASH and T2D are expected to be recruited in the trial.

The non-cirrhotic NASH diagnosis in the trial will be based on a historic histology assessment or a combination of non-invasive techniques, such as imaging and serum-based metabolic diagnostic tests.

The company noted that the Phase IIa study will provide information regarding the evolution of body weight and body fat composition in NASH and T2D patients when treated with lanifibranor in combination with empagliflozin.

Inventiva chief medical officer Dr. Michael Cooreman said: “We are delighted to see the initiation of this Proof-of-Concept study, which we believe will further draw attention to NASH as a multisystemic liver disease with a highly relevant cardiometabolic aspect.

“This clinical trial is anticipated to not only add to the body of evidence demonstrating the therapeutic benefits of lanifibranor on the broad spectrum of the disease biology of NASH, but should also provide insights on how the complementary mechanisms of action of a pan-PPAR agonist and an SGLT2 inihibitor could enhance the therapeutic benefits of lanifibranor.”

Change in Hemoglobin A1c (HbA1c) at the end of the 24-week treatment will be the study’s primary efficacy endpoint.

Changes in body fat composition, liver enzymes, inflammatory markers, and glycaemic and lipids parameters will be some of the secondary endpoints of the study.

More than 30 sites the UK, Belgium, France, Netherlands, and the US have already been qualified to participate in the study.

The topline data from the trial are expected to be published in the second half of next year.

Fri, 08 Jul 2022 02:00:00 -0500 en-US text/html https://www.clinicaltrialsarena.com/news/inventiva-nash-type-2-diabetes-treatment/
Killexams : Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) webinar on its proprietary Human Acellular Vessels (HAV™) in the treatment of vascular trauma on Thursday, July 14, 2022 at 11:30 a.m. Eastern Time.

The webinar will feature presentations from KOLs Ernest E. Moore, MD (Denver Health) and Gregory A. Magee, MD, (Keck Medicine, University of Southern California), who will discuss the current treatment landscape and unmet medical need in the vascular trauma field as well as case studies of trauma patients treated with the HAV.

Humacyte’s HAV are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is designed to eliminate the need for harvesting a vessel from a patient or using a synthetic graft, and clinical evidence to date suggests that it is non-immunogenic and infection-resistant and can become durable living tissue.

A question and answer session will follow the formal presentations. To register for the event, please click here.

Ernest E. “Gene” Moore, MD, was the Chief of Trauma at the Denver General Hospital for 36 years, Chief of Surgery for 28 years, and the first Bruce M. Rockwell Distinguished Chair in Trauma Surgery. He continues to serve as Vice Chairman for Research and is a Distinguished Professor of Surgery at the University of Colorado Denver (UCD) and was the Editor of the Journal of Trauma 2011-2021.

Under Dr. Moore’s leadership, the Rocky Mountain Regional Trauma Center at Denver General became internationally recognized for innovative care of the injured patient, and its trauma research laboratory has been funded by the NIH for 35 consecutive years. In July 2018, the center was renamed the Ernest E Moore Shock Trauma Center at Denver Health.

Dr. Moore has served as president of ten academic societies, including the Society of University Surgeons, American Association for the Surgery of Trauma, International Association for the Trauma and Surgical Intensive Care, and the World Society of Emergency Surgery; and as Vice President for the American Surgical Association.

His awards include the Robert Danis Prize from the Society of International Surgeons, Orazio Campione Prize from the World Society of Emergency Surgery, Philip Hench Award from the University of Pittsburgh, Florence Sabin Award from the University of Colorado, Lifetime Achievement Award from the Society of University Surgeons, Lifetime Achievement Award for Resuscitation Science from the American Heart Association, Distinguished Investigator Award from the American College of Critical Medicine, Distinguished Investigator Award from the Shock Society, Lifetime Service Award from the International Association for Trauma and Surgical Intensive Care, and the Medallion for Scientific Achievement from the American Surgical Association. He has honorary fellowships in the Royal College of Surgeons of Edinburgh, the Royal College of Surgeons in Ireland, the Royal College of Surgeons of Thailand, and the American College of Emergency Physicians; and is an honorary member of the Brazilian Trauma Society, Colombian Trauma Society, Eastern Association for the Surgery of Trauma, European Society for Trauma and Emergency Surgery, North Pacific Surgical Association, and Trauma Association of Canada. Dr. Moore is coeditor of the textbook Trauma, in its 9th edition, Surgical Secrets in its 7th edition, and Trauma Induced Coagulopathy, in its 2nd edition; he has >2000 publications and has lectured extensively throughout the world.

Gregory A. Magee, MD received his BA in Molecular Biophysics & Biochemistry from Yale University and his MSc in Applied Statistics from the University of Oxford. He earned his medical degree from Yale School of Medicine in 2006.

Dr. Magee underwent his general surgery residency at Stanford. During his two research years, Dr. Magee completed the Stanford Biodesign Surgical Innovation Fellowship, developing devices that formed the basis for two venture-funded start-up companies, both of which are currently conducting clinical trials. He continues to pursue his goal of improving medical care through technological innovation.

Dr. Magee completed a surgical critical care and trauma surgery fellowship at USC from 2013–2015 and a vascular surgery fellowship at the University of Colorado Denver in 2017, where he developed a broad experience in complex endovascular repair of the entire aorta using tailor-made fenestrated grafts. He is board certified in General Surgery, Surgical Critical Care, and Vascular Surgery.

About HAV
Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement – it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue. The HAV is currently being evaluated in two Phase 3 trials in arteriovenous access and a Phase 2/3 trial for vascular trauma, and has been used in more than 460 patient implantations. Humacyte’s 6mm HAV for AV access for performing hemodialysis was the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), and has also received FDA Fast Track designation. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to Improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
media@humacyte.com

Thu, 07 Jul 2022 00:03:00 -0500 en text/html https://apnews.com/press-release/globe-newswire/health-denver-trauma-university-of-southern-california-01927072c0bdfd9e5f279946aabe91fb
Killexams : Mild to moderate COVID causes inflammation of white matter in brain ten months later

In a latest work published in the medRxiv* preprint server, scientists in Germany performed neuropsychological evaluations and brain imaging of people who recovered from mild to moderate coronavirus disease 2019 (COVID-19).

Study: Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection. Image Credit: Shyntartanya / Shutterstock Study: Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection. Image Credit: Shyntartanya / Shutterstock

Background

Analyzing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)'s long-term effects on health outcomes has received immense attention as more people recover from acute infections with the virus. According to previous reports, COVID-19 exerts a significant influence on the central nervous system. It is, therefore, crucial to assess the effects of COVID-19 on brain structure and neuropsychological function in order to help guide future medical treatments.

Most postmortem histopathological and molecular investigations were performed in severe COVID-19 patients. On the other hand, histological results from people with mild to moderate COVID-19 are scarce. In vivo investigations using advanced brain imaging techniques combined with thorough neuropsychological and clinical evaluations are also limited.

On the whole, there is a requirement for additional research in light of the current evidence's limited applicability to individuals with a mild to moderate SARS-CoV-2 infection.

About the study

In the present work, the researchers explored the potential associations between mild to moderate SARS-CoV-2 infection and changes in brain structure seen on magnetic resonance imaging (MRI) scans and neuropsychological abnormalities.

The scientists used modern MRI techniques to explore the imaging phenotypes connected to neurodegeneration, atrophy, cellular/myelin disruption, inflammation, and vascular damage. Participants in the study also underwent thorough neuropsychological and clinical evaluations. 

The team followed a retrospective, cross-sectional, case-control design and included 223 non-vaccinated individuals with a SARS-CoV-2-positive polymerase chain reaction test (PCR) obtained between March 1 and December 31, 2020, and received neuropsychological and MRI evaluations within the template of the Hamburg City Health Study with an average 9.7 months upon testing. Further, 223 healthy controls analyzed ahead of the COVID-19 pandemic were selected from the main study and matched for sex, age, cardiovascular risk variables, and education levels.

A positive PCR test Checked the SARS-CoV-2 infection. Advanced diffusion MRI measurements of cortical thickness, white matter microstructure, scores of neuropsychological tests, and white matter hyperintensity (WMH) load were the primary study outcomes.

Results 

Overall, the study results indicated that the current analysis included 223 mild-moderate COVID-19 convalescent individuals encompassing 100 females, 123 males aged 55.54 +- 7.07, and 223 matched healthy controls comprising 93 females, 130 males aged 55.74 +- 6.60. 

Of the 11 MR imaging indicators assessed, substantial variations between cohorts were observed in global measurements of extracellular free-water and mean diffusivity (MD), both of which were higher in the white matter of SARS-CoV-2 recovered people relative to matched controls. The observed rise in MD and free water may be a subliminal indicator of a protracted neuroinflammatory response to SARS-CoV-2 infection.

However, the investigators noted that additional probable pathways for alterations in the extracellular space should be considered. Furthermore, the current data imply that, rather than structural neural damage, variations in the white matter after a mild to moderate SARS-CoV-2 infection most probably indicate minor elevations in extracellular free water.

There were no discernible differences in cortical thickness or indicators of cerebral small vessel disease across the groups. Although previously documented, a mild to moderate course of COVID-19 did not result in visually apparent vascular lesions, i.e., WMH, as evidenced by the fact that WMH load was not substantially different.

Classification accuracy for identifying post-COVID-19 patients according to diffusion imaging markers, including white matter diffusion indices, was about 80%. Given that fiber cross-section accuracy was more accurate than cortical thickness, it was possible that COVID-19-related changes preferentially affect the white matter. Besides, neuropsychological test results did not drastically vary between the groups.

The results of this study suggest that mild to moderate COVID-19 infection is associated with mild microstructural abnormalities in cerebral white matter after acute infection.

Conclusions

Collectively, in the current research, the authors conducted a thorough assessment of known neuroimaging indicators for structural neural integrity to describe neurobiological shifts that could underlie post-acute COVID-19 neuropsychological consequences after a primarily mild to moderate illness course.

The study findings imply that minute alterations in the extracellular water level of white matter could persist after an acute SARS-CoV-2 infection. Nonetheless, within the initial year following recovery, mild to moderate COVID-19 was not linked in the current group to neuropsychological deficits, notable changes in cortical structure or vascular abnormalities. The team mentioned that longitudinal follow-up studies and external validation of the present findings were required to elucidate their clinical implications.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:

Mon, 11 Jul 2022 17:04:00 -0500 en text/html https://www.news-medical.net/news/20220712/Mild-to-moderate-COVID-causes-inflammation-of-white-matter-in-brain-ten-months-later.aspx
Killexams : Vascular Institute Opens Clinic In Dayton

The Vascular Institute announces the opening of its fifth location in Dayton at 7693 Rhea County Hwy.

The office will be open every Thursday, beginning this week, to serve patients’ general
vascular appointments, as well as perform diagnostic ultrasounds.

"Ashley Elledge, FNP-BC will lead this office and deliver compassionate, convenient and quality care for her patients," officials said.

New patient appointments are being scheduled now by calling 423-602-2750.

“The VIC Team is very excited to be in Dayton, and for the opportunity to serve the region.
Access to care is critical for vascular patients. By opening an office in the community, it will allow
for patients to be triaged, seen and diagnosed quickly,” said Dr. Chris LeSar.

The VIC Vascular Team consists of Dr. Chris LeSar, Dr. Elizabeth Hartmann and Dr. William Harris, who specialize in all aspects of vascular surgery. Surgeons perform procedures in the VIC Chattanooga and Cleveland Outpatient Surgical centers, as well as all area hospitals, including Parkridge, Erlanger, Tennova and CHI Memorial.

Sat, 09 Jul 2022 12:00:00 -0500 en text/html https://www.chattanoogan.com/2022/1/17/441689/Vascular-Institute-Opens-Clinic-In-Dayton.aspx
Killexams : Preventing dementia in your 60s: How blood pressure matters No result found, try new keyword!The numbers don’t lie. After we turn 60, up to 8% of us will live with dementia. And now, one latest study has correlated both dementia and mild cognitive impairment with heart health—especially heart ... Wed, 06 Jul 2022 09:42:30 -0500 en-us text/html https://www.msn.com/en-us/health/medical/preventing-dementia-in-your-60s-how-blood-pressure-matters/ar-AAZhU2S Killexams : Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) webinar on its proprietary Human Acellular Vessels (HAV™) in the treatment of vascular trauma on Thursday, July 14, 2022 at 11:30 a.m. Eastern Time.

The webinar will feature presentations from KOLs Ernest E. Moore, MD (Denver Health) and Gregory A. Magee, MD, (Keck Medicine, University of Southern California), who will discuss the current treatment landscape and unmet medical need in the vascular trauma field as well as case studies of trauma patients treated with the HAV.

Humacyte’s HAV are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is designed to eliminate the need for harvesting a vessel from a patient or using a synthetic graft, and clinical evidence to date suggests that it is non-immunogenic and infection-resistant and can become durable living tissue.

A question and answer session will follow the formal presentations. To register for the event, please click here.

Ernest E. “Gene” Moore, MD, was the Chief of Trauma at the Denver General Hospital for 36 years, Chief of Surgery for 28 years, and the first Bruce M. Rockwell Distinguished Chair in Trauma Surgery. He continues to serve as Vice Chairman for Research and is a Distinguished Professor of Surgery at the University of Colorado Denver (UCD) and was the Editor of the Journal of Trauma 2011-2021.

Under Dr. Moore’s leadership, the Rocky Mountain Regional Trauma Center at Denver General became internationally recognized for innovative care of the injured patient, and its trauma research laboratory has been funded by the NIH for 35 consecutive years. In July 2018, the center was renamed the Ernest E Moore Shock Trauma Center at Denver Health.

Dr. Moore has served as president of ten academic societies, including the Society of University Surgeons, American Association for the Surgery of Trauma, International Association for the Trauma and Surgical Intensive Care, and the World Society of Emergency Surgery; and as Vice President for the American Surgical Association.

His awards include the Robert Danis Prize from the Society of International Surgeons, Orazio Campione Prize from the World Society of Emergency Surgery, Philip Hench Award from the University of Pittsburgh, Florence Sabin Award from the University of Colorado, Lifetime Achievement Award from the Society of University Surgeons, Lifetime Achievement Award for Resuscitation Science from the American Heart Association, Distinguished Investigator Award from the American College of Critical Medicine, Distinguished Investigator Award from the Shock Society, Lifetime Service Award from the International Association for Trauma and Surgical Intensive Care, and the Medallion for Scientific Achievement from the American Surgical Association. He has honorary fellowships in the Royal College of Surgeons of Edinburgh, the Royal College of Surgeons in Ireland, the Royal College of Surgeons of Thailand, and the American College of Emergency Physicians; and is an honorary member of the Brazilian Trauma Society, Colombian Trauma Society, Eastern Association for the Surgery of Trauma, European Society for Trauma and Emergency Surgery, North Pacific Surgical Association, and Trauma Association of Canada. Dr. Moore is coeditor of the textbook Trauma, in its 9th edition, Surgical Secrets in its 7th edition, and Trauma Induced Coagulopathy, in its 2nd edition; he has >2000 publications and has lectured extensively throughout the world.

Gregory A. Magee, MD received his BA in Molecular Biophysics & Biochemistry from Yale University and his MSc in Applied Statistics from the University of Oxford. He earned his medical degree from Yale School of Medicine in 2006.

Dr. Magee underwent his general surgery residency at Stanford. During his two research years, Dr. Magee completed the Stanford Biodesign Surgical Innovation Fellowship, developing devices that formed the basis for two venture-funded start-up companies, both of which are currently conducting clinical trials. He continues to pursue his goal of improving medical care through technological innovation.

Dr. Magee completed a surgical critical care and trauma surgery fellowship at USC from 2013–2015 and a vascular surgery fellowship at the University of Colorado Denver in 2017, where he developed a broad experience in complex endovascular repair of the entire aorta using tailor-made fenestrated grafts. He is board certified in General Surgery, Surgical Critical Care, and Vascular Surgery.

About HAV
Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement – it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue. The HAV is currently being evaluated in two Phase 3 trials in arteriovenous access and a Phase 2/3 trial for vascular trauma, and has been used in more than 460 patient implantations. Humacyte’s 6mm HAV for AV access for performing hemodialysis was the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), and has also received FDA Fast Track designation. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to Improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
media@humacyte.com


Primary Logo

Thu, 07 Jul 2022 00:36:00 -0500 en-US text/html https://fox8.com/business/press-releases/globenewswire/8585152/humacyte-hosting-key-opinion-leader-webinar-on-human-acellular-vessels-in-the-treatment-of-vascular-trauma/
VACC exam dump and training guide direct download
Training Exams List